[Lung Cancer Precision Medicine] New Oral Targeted Option: Mobocertinib Receives FDA Breakthrough Approval for EGFR Exon 20 Insertion Mutations

Mobocertinib: A New Targeted Treatment for EGFR Exon 20 Insertion Mutations

For patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, treatment is shifting from conventional chemotherapy toward more precise targeted therapy. The US FDA granted accelerated approval to the oral drug Mobocertinib for patients whose disease has progressed following platinum-based chemotherapy, offering a more convenient treatment option for this specific mutation group.

1. Clinical Trial 101: Interpreting Efficacy Data

The approval is primarily based on data from the international multicenter Clinical Trial 101 (NCT02716116).

Key Performance Metrics:

• Objective Response Rate (ORR): 28%
• Median Duration of Response (DoR): 17.5 months
• Convenience: Once-daily oral 160 mg dosing significantly improves patient quality of life compared to drugs requiring inpatient infusion

2. Safety Profile and Side Effect Alerts

While Mobocertinib offers convenience, side effect management is equally critical. Japanese specialist medical teams pay particular attention to:

• Common gastrointestinal reactions: Diarrhea (≥20%), nausea, vomiting
• Skin and mucosal reactions: Rash, paronychia, stomatitis
• Cardiac toxicity monitoring: Close attention to QTc interval prolongation; regular ECG monitoring is recommended

3. Companion Diagnostics: The Key to Precision Medicine

Alongside Mobocertinib, the Oncomine Dx Target Test — an advanced genetic testing tool — was also approved. Leading Japanese hospitals typically use such precision tests to accurately identify patients eligible for this treatment, ensuring therapeutic efficacy.

Medical Supporter Connects You to Japan's Advanced Medical Care

Facing a rare mutation, access to accurate information and appropriate treatment pathways is critical. The Medical Supporter team can assist with medical record translation and facilitate communication with Japan's leading lung cancer specialists to assess the feasibility of Mobocertinib or other latest targeted therapies in your treatment plan.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Lung cancer